Noninvasive methods of diagnosis of steatosis in non-alcoholic fatty liver disease
https://doi.org/10.31146/1682-8658-ecg-177-5-61-66
Abstract
The aim of the research: to study the diagnostic capabilities of non-invasive methods for the diagnosis of hepatic steatosis in patients with NAFLD.
Materials and methods: the study included 240 male patients aged 21 to 54 years (mean age 41,1 ± 8,1 years), 172 of them with non-alcoholic fatty liver disease, 68 without this pathology. All performed measurement of anthropometric parameters, biochemical study of blood serum, ultrasound examination of the hepatobiliary zone, calculation of diagnostic indices of steatosis (FLI and HSI), non-invasive determination of the degree of steatosis on the device FibroScan with function CAP.
Results: the CAP values of the FibroScan apparatus, as well as indicators of predictive steatosis indices signifi cantly (p<0,05) diff ered in the study groups; the quality of diagnostic models, estimated by the AUROC index, in the steatosis indices FLI and HIS was recognized as excellent, in the CAP values of the FibroScan apparatus as very good.
Keywords
About the Authors
I. I. Zhirkov
Federal state budgetary military educational institution of higher education “S. M. Kirov Military medical Academy” of the Defense Ministry of the Russian Federation
Russian Federation
Igor I. Zhirkov, Department of Hospital Therapy
Saint-Petersburg
Russian Federation
Igor I. Zhirkov, Department of Hospital Therapy
Saint-Petersburg
A. V. Gordienko
Federal state budgetary military educational institution of higher education “S. M. Kirov Military medical Academy” of the Defense Ministry of the Russian Federation
Russian Federation
Russian Federation
Alexander V. Gordienko, Department of Hospital Therapy, Professor, M.D.
Saint-Petersburg
I. M. Pavlovich
Federal state budgetary military educational institution of higher education “S. M. Kirov Military medical Academy” of the Defense Ministry of the Russian Federation
Russian Federation
Russian Federation
Igor M. Pavlovich, Department of Hospital Therapy, Professor, M.D
Saint-Petersburg
V. Yu. Golofeevsky
Federal state budgetary military educational institution of higher education “S. M. Kirov Military medical Academy” of the Defense Ministry of the Russian Federation
Russian Federation
Russian Federation
Vyacheslav Yu. Golofeevsky, Department of Military Therapy, Professor, M.D.
Saint-Petersburg
O. V. Makoveeva
Federal state budgetary military educational institution of higher education “S. M. Kirov Military medical Academy” of the Defense Ministry of the Russian Federation
Russian Federation
Russian Federation
Olga V. Makoveeva, Department of Hospital Therapy, Senior Lecturer;
Saint-Petersburg
References
1. Younossi Z. M., Koenig A. B., Abdelatif D. et al. Global epidemiology of nonalcoholic fatty liver disease – meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 2016, Vol. 63, pp. 73–84.
2. Лазебник Л. Б., Радченко В. Г., Голованова Е. В. и соавт. Неалкогольная жировая болезнь печени: клиника, диагностика, лечение (рекомендации для терапевтов, 2-я версия) // Экспер. и клин. гастроэнтерол. – 2017. – № 2 (138). – С. 22–37. Lazebnik L. B., Radchenko V. G., Golovanova E. V., et al. Nonalcoholic fatty liver disease: clinic, diagnostics, treatment (Recommendations for therapists, 2nd edition). Experimental and Clinical Gastroenterology. 2017;(2):22–37. (In Russ.)
3. Ивашкин В. Т. Драпкина О. М., Маев И. В. и соавт. Распространенность неалкогольной жировой болезни печени у пациентов амбулаторно-поликлинической практики в Российской Федерации: результаты исследования DIREG 2 // Рос. журн. гастроэнтерол. гепатол. колопроктол. – 2015. – № 6. – С. 31–41. Ivashkin V. T., Drapkina O. M., Mayev I. V. et al. Prevalence of non-alcoholic fatty liver disease in out-patients of the Russian Federation: DIREG 2 study results. Russian Journal of Gastroenterology. Hepatology, Coloproctology, 2015, Vol. 25, no. 6, pp. 31–41. (In Russian)
4. Жирков И. И., Гордиенко А. В., Гуляев Н. И. и соавт. Хронические диффузные заболевания печени невирусной этиологии у военнослужащих // Вестн. Росс. воен.-мед. акад. – 2019. – № 4 (68). – С. 72–76. Zhirkov I. I., Gordienko A. V., Gulyaev N. I. et al. Chronic diffuse liver disease of non-viral etiology in the military. Vestnik rossiyskoy voyenno-meditsinskoy akademii, 2019, Vol. 68, no. 4, pp. 72–76. (In Russian)
5. EASL-EASD-EASO Clinical Practice Guideline for the management of non-alcoholic liver disease. European Association for the Study of the Liver (EASL) and European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO). Diabetologia, 2016, Vol. 59, pp. 1121–1140.
6. Bedossa, P. FLIP Pathology Consortium. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology, 2014, Vol. 60, pp. 565–575.
7. Long Wang, Jinghui Guo, Jianping Lu. Risk factor compositions of nonalcoholic fatty liver disease change with body mass index in males and females. Oncotarget. – 2016, Vol. 7, no. 24, pp. 35632–35642.
8. Sasso M., Tengher-Barna I., Ziol M. et al. Controlled attenuation parameter (CAP): a novel VCTE® guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med. Biol, 2010, Vol. 36, no. 11, pp. 1825–1835.
9. Chon Y. E., Jung K. S., Kim S. U. et al. Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population. Liver Int, 2014, Vol. 34, no. 1, pp. 102–109.
10. Masaki K., Takaki S., Hyogo H. et al. Utility of controlled attenuation parameter measurement for assessing liver steatosis in Japanese patients with chronic liver diseases. Hepatol. Res. 2013, Vol. 43, no. 11, pp. 1182–1189.
11. Yoneda M. Utility of controlled attenuation parameter measurement for assessing liver steatosis in Japanese patients with chronic liver disease. Hepatol. Res, 2013, Vol. 43, no. 11, pp. 1125–1126.
12. de Lédinghen V, Vergniol J., Foucher J. et al. Noninvasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int, 2012, Vol. 32, no. 6, pp. 911–918.
13. Bedogni G., Bellentani S., Miglioli L. et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol, 2006, no. 6, 33 p.
14. Kotronen A., Peltonen M., Hakkarainen A. et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology, 2009, Vol. 137, no. 3, pp. 865–872.
15. Lee J. H., Kim D., Kim H. J. et al. Hepatic steatosis index: a simple screening tool refl ecting nonalcoholic fatty liver disease. Dig. Liver Dis, 2010, Vol. 42, pp. 503–508.
16. Poynard T., Ratziu V., Naveau S. et al. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp. Hepatol, 2005, Vol. 4, pp. 1–10.
Review
For citations:
Zhirkov I.I., Gordienko A.V., Pavlovich I.M., Golofeevsky V.Yu., Makoveeva O.V. Noninvasive methods of diagnosis of steatosis in non-alcoholic fatty liver disease. Experimental and Clinical Gastroenterology. 2020;174(5):61-66. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-177-5-61-66
Views:
604
Email this article 